This 12 months’s presidential election is already sending health-care stocks on a wild ride. Historically, shifts in political control have created “increased volatility” across the health care sector, sending investors “to search for areas of safety,” Raymond James analyst Chris Meekins said in a July 7 note. “This election is prone to produce distinct, binary, opposing health policy outcomes depending on who wins.” With Inexpensive Care Act subsidies set to run out next 12 months and scrutiny of Medicare Advantage plans intensifying in recent months, health insurers could also be much more sensitive to this pattern than usual. Indeed, it already appears evident in how managed-care stocks are trading. At the beginning of the week, traders appeared to have come to the conclusion that former U.S. President Donald Trump was amassing an unbeatable lead against Joe Biden . The present president’s reelection campaign has been struggling since Biden’s disastrous debate performance on June 27. Calls for him to bow out of the race quieted briefly after a failed assassination attempt against Trump, but on Thursday pressure was constructing once more. A have a look at how UnitedHealth Group shares have traded amid these headlines gives a way of the swings in sentiment. As of Thursday’s close, the stock had been underperforming the market with a 7% gain 12 months up to now. Nevertheless, because the presidential debate, the shares are up nearly 17%. The stock hit a fresh 52-week high in trading Wednesday, but has moved off its high in recent sessions because it began to look as if Biden might step aside . UNH 1M mountain UnitedHealth stock over the past month. The broader health-care sector, a defensive, “late-cycle” group, generally struggles in election years and the 12 months after — and historically outperforms the second 12 months after an election, Meekins noted. Most health-care sectors also perform “a lot better” when a Republican wins the presidency. The broad universe of health-care stocks has underperformed by roughly 19% through the Biden presidency, the analyst said. What a GOP victory means Analysts expect Republican leadership would lessen regulatory scrutiny by the Federal Trade Commission and Department of Justice, while still tamp down drug prices. Nevertheless, it could mean the tip of expanded individual health-care subsidies. That is necessary because this profit, which was established under the ACA, or Obamacare, reduces the monthly premiums and out-of-pocket costs for middle- and low-income individuals. It is about to run out at the tip of 2025, and a GOP sweep could assure that. Raymond James’ Meekins said the tip of subsidies may lead to a lot of newly uninsured people, hurting hospitals and managed-care firms, which might see lower enrollment. On the flip side, analysts see a Trump win as a positive for Medicare Advantage carriers. Think Centene , Molina Healthcare , UnitedHealth and Humana , amongst others. Medicare Advantage is a form of Medicare health plan offered by private insurance firms that, through annual contracts, generally provide the identical coverage as original Medicare, but often with additional advantages akin to vision and dental coverage. “A Trump administration can be more favorable from a rate perspective, which can help alleviate a few of the cost issues [Medicare Advantage carriers] have been feeling and the pressure they have been feeling on the medical costs side, in comparison with what they’ve experienced under the Biden administration to this point,” Meekins said. History bodes well for the group. Managed-care firms historically buck the broader trend of health stocks and outperform in the primary 12 months after an election, in accordance with Raymond James. Analysts from several firms, including Raymond James, Bernstein and RBC Capital Markets, imagine UnitedHealth, Humana and CVS Health can be amongst the most important beneficiaries of a Trump win. Recent gains at UnitedHealth, the most important private insurer within the U.S., not only reflect the shifting political winds. There was a turnaround in investor enthusiasm attributable to a powerful second quarter that reignited confidence in the corporate’s outlook. Jefferies analyst David Windley praised the corporate’s efforts to pinch costs, saying it may lead to a “superior ’25 setup” for the stock. Windley sees a Trump win leading to membership growth, and UnitedHealth appears “best positioned to capture the complete economic opportunity.” He holds a buy rating and $647 price goal on the stock, which means the shares could jump nearly 15% from Thursday’s close. RBC Capital Markets analyst Ben Hendrix said UnitedHealth would see probably the most immediate upside among the many managed-care organizations under a Trump administration as its Optum unit would profit from an easing regulatory environment. Optum has helped fuel the corporate’s record profits by offering a variety of primary-care, specialty and urgent-care services to almost 104 million consumers . In late February, the DOJ launched an antitrust investigation to look into the role giant conglomerates have played in rising health-care costs. Alongside UnitedHealth and Humana, Raymond James analyst John Ransom also expects managed-care provider Alignment Healthcare to learn from a GOP sweep, as he said these three names have relatively high exposure to Republican-favored Medicare Advantage plans and fewer or none to the ACA. Humana has lost greater than 15% this 12 months, but like UnitedHealth, its shares have risen nearly 8% because the presidential debate. Piper Sandler initiated coverage of Humana with an chubby rating and $392 price goal on June 25, saying a “turnaround” for the corporate is underway, aided by a latest CEO and the expected growth within the Medicare Advantage market. “We predict the HUM brand has a permanent competitive moat … and we imagine the corporate’s purpose-built healthcare delivery and services infrastructure should improve outcomes and bend the fee curve through center-based, at-home and pharmacy care over time,” the firm said, adding that the stock is cheaper than it appears. Telehealth and prescription drug provider GoodRx Holdings could also get a lift if a Republican sweep eliminates the ACA-enhanced subsidies, Ransom said. Shares are up greater than 20 % 12 months up to now. “With the potential for hundreds of thousands of ACA members to lose insurance coverage, we imagine GDRX could stand to learn as individuals would increasingly seek prescription savings,” he said. What a Democratic victory means If Democrats overcome their recent struggles, either with Biden or one other candidate, analysts see managed-care names linked to the ACA and hospitals as winners. On this scenario, Bernstein analyst Lance Wilkes expects Centene to learn because the largest Medicaid managed-care organization. He has an outperform rating and bullish $94 price goal on the stock, suggesting greater than 43% potential upside. “We’d see some stock price headwinds for CNC, but more limited attributable to valuation levels and lower deal with Medicaid reform this time,” he said. Centene shares are down greater than 11% 12 months up to now. Unlike UnitedHealth, shares have fallen — down 3% — because the June debate. Raymond James sees Oscar Health , HCA Healthcare and Tenet Healthcare as beneficiaries of a victory by the left. “A Democratic sweep would almost guarantee an extension of the Inexpensive Care Act expanded subsidies, which can be a transparent positive for OSCR,” Ransom said. About 95% of its membership comes from the ACA exchanges. Shares of Oscar Health are up a whopping 64% this 12 months, however the stock has fallen 17% because the debate aired. It could also profit HCA and Tenet Healthcare, given the pair’s exposure to Florida and Texas, he said. The 2 markets comprise roughly 36% of total ACA enrollment. When Raymond James initiated Oscar in late March with an outperform rating and $20 price goal — now 33% higher than the stock’s latest close — Ransom acknowledged its fortunes can be sensitive to news around ACA subsidies. Nevertheless, he expects Oscar’s latest chief executive, the previous head of CVS Health -owned Aetna, to spice up earnings growth through cost cutting.
Abortion pill mifepristone access regular under Trump, FDA review looms
Mifepristone and Misoprostol pills are pictured Wednesday, Oct. 3, 2018, in Skokie, Illinois.Erin Hooley | Chicago Tribune | Tribune News...
